Advances in Management of Stable Coronary Artery Disease: the Role of Revascularization?
- 108 Downloads
Purpose of review
Coronary artery disease remains the most common cause of death worldwide. In patients with biomarker-positive acute coronary syndrome, the combination of guideline-directed medical therapy with routine revascularization is associated with improved outcomes. However, the role of routine revascularization in stable ischemic heart disease, in addition to medical therapy, remains a matter of debate. In this review, we aimed to describe the role of revascularization in stable ischemic heart disease.
Revascularization is indicated in patients with stable ischemic heart disease and progressive or refractory symptoms, despite medical management. When guided by ischemia presence, revascularization has failed to show survival benefit, compared with medical therapy alone in multiple clinical trials. On the other hand, revascularization guided by coronary lesion severity, assessed by FFR or iFR, has been shown to offer survival benefit and improvement in symptom severity. PCI-revascularization of unprotected left main disease is feasible with comparable to surgical approach outcomes.
Clinical decision to perform revascularization in stable ischemic heart disease necessitates a heart team approach, and no simple algorithm can guide this process. Further studies are required to assess the benefit of routine revascularization, in combination to medical therapy, in this population.
KeywordsStable coronary artery disease Ischemic heart disease Revascularization Percutaneous coronary intervention Coronary artery bypass graft
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 7.Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010;55(22):2435–45.CrossRefGoogle Scholar
- 10.• Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 2014;64(18):1929–49 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease.Google Scholar
- 11.Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.CrossRefGoogle Scholar
- 17.Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010;121(24):2645–53.CrossRefGoogle Scholar
- 18.Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629–38.CrossRefGoogle Scholar
- 21.Brooks MM, Chaitman BR, Nesto RW, Hardison RM, Feit F, Gersh BJ, et al. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2012;126(17):2115–24.CrossRefGoogle Scholar
- 24.• Stone GW, Hochman JS, Williams DO, Boden WE, Ferguson TB Jr, Harrington RA, et al. Medical therapy with versus without revascularization in stable patients with moderate and severe ischemia: the case for community equipoise. J Am Coll Cardiol. 2016;67(1):81–99 ISCHEMIA trial designed to address the benefit of routine revascularization in combination with medical therapy. Results expected in 2019.CrossRefGoogle Scholar
- 26.Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LE, Friedman JD, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32(8):1012–24.CrossRefGoogle Scholar
- 27.Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation. 2003;107(23):2900–7.CrossRefGoogle Scholar
- 29.•• Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, et al. Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med. 2015;373(20):1937–46 The results of COURAGE trial comparing PCI with optimal medical therapy to optimal medical therapy alone.CrossRefGoogle Scholar
- 30.Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117(10):1283–91.CrossRefGoogle Scholar
- 31.Shaw LJ, Weintraub WS, Maron DJ, Hartigan PM, Hachamovitch R, Min JK, et al. Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J. 2012;164(2):243–50.CrossRefGoogle Scholar
- 33.•• Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31–40 The original ORBITA trial comparing PCI and intensive optimal therapy or intensive optimal therapy and a sham procedure.CrossRefGoogle Scholar
- 35.•• Bittner V, Bertolet M, Barraza Felix R, Farkouh ME, Goldberg S, Ramanathan KB, et al. Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial. J Am Coll Cardiol. 2015;66(7):765–73 BARI 2D sub-analysis showing the importance of excellent risk factor control through protocol-guided intensive medical therapy.CrossRefGoogle Scholar
- 36.Stergiopoulos K, Boden WE, Hartigan P, Mobius-Winkler S, Hambrecht R, Hueb W, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014;174(2):232–40.CrossRefGoogle Scholar
- 38.Rioufol G, et al. FUTURE trial: treatment strategy in multivessel coronary disease patients based on fractional flow reserve. Presented at ESC 2018; August 25, 2018; Munich, Germany.Google Scholar
- 39.•• Al-Lamee R, Howard JP, Shun-Shin MJ, Thompson D, Dehbi HM, Sen S, et al. Fractional flow reserve and instantaneous wave-free ratio as predictors of the placebo-controlled response to percutaneous coronary intervention in stable single-vessel coronary artery disease. Circulation. 2018;138(17):1780–92 Physiology-stratified analysis of ORBITA trial demonstrating benefit of PCI-revascularization on stress ECHO score and patient reported freedom from angina.CrossRefGoogle Scholar
- 40.• Norgaard BL, Terkelsen CJ, Mathiassen ON, Grove EL, Botker HE, Parner E, et al. Coronary CT angiographic and flow reserve-guided management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2018;72(18):2123–34 Use of CTA and FFRCT testing successfully differentiated patients who did not require further diagnostic testing or intervention (FFRCT > 0.80) from higher-risk patients (FFRCT ≤ 0.80) in whom further testing with invasive coronary angiography and possibly intervention may be required.Google Scholar
- 46.•• Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018;391(10124):939–48 Metanalysis demonstrating similar all-cause mortality at 5 years between PCI and CABG revascularization of left main disease, regardless of diabetes status and SYNTAX score.CrossRefGoogle Scholar